Our Company

As part of the multinational pharmaceutical company EMS (NC Group), our main mission is to design and develop a well-balanced preclinical and clinical pipeline, mainly based on the concept of repositioning existing drugs in the areas of Gastroenterology, Ophthalmology, Dermatology, manufactured with innovative drug delivery systems, to deal with unmet patients’ needs or new emerging diseases, including Rare Diseases.

We are keen on evaluating strategical Business-to-Business (B2B) partnerships or co-development projects to re-design a repositioning project starting from the early conceptual phases (drug delivery design, early pharmaco-economical evaluation, regulatory pattern definition through the main international agencies), until the execution phase, taking care of the Investigational Medicinal Product (IMP) for clinical Proof of Concept (PoC) / First in Human (FiH) trials.

In addition, Monteresearch acts also as a Contract Development Manufacturing Organization (CDMO), operating full pharmaceutical services for our partners.

Key Targets

To In-License early-stage Oral Peptides / Oligos and technologies thereof in needs of PoC clinical evidence in selected therapeutic areas including gastro-intestinal diseases.

To In-License early-stage opportunities addressing the repositioning of small molecules mainly intended for gastro-intestinal diseases.

We are open to co-development or partnering with other Pharma companies either small molecules or peptides joining expertise to successfully reach the clinical and registration phases.

Should you have opportunities of repositioning (early-phase projects or ideas) which fit with the aforementioned areas of expertise, we will be happy to get in touch and discuss any possible new business opportunities.